The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
MPH!
02/04- The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study
“FDA already awarded Fast Track designation and already agreed in principle on an outline for a phase II clinical trial that could potentially support accelerated approval of navicixizumab in patients with ovarian cancer who have become resistant to prior therapies."
Very rough but $300,000,000 / 124507857 $2.40 or £1.94
Following the successful end of Phase2 meeting with FDA there is apparently a thought elsewhere that BCT-197 may have a use in treating CV19. AECOPD in COPD patients- AECOPDs occur in the natural course of the disease but are commonly triggered by infections and air pollution. BCT-197 aims to address the airway and systemic inflammation that are characteristic drivers of the disease and to reduce the frequency of subsequent severe AECOPDs. Not my view but if there is a possibility then a move to Stage 3 may come sooner rather than later.
Up 20% on nasdaq.
Up 13% in the US
Would be nice to see some movement coming into April.
remain .
Auto-correct .
Best of
Fairly unrealistic in fact .
But , the study of the respiratory system and It`s management may have some Interlinks .
One never knows for certain , until one has tried . What will bring forward the ultimate vaccine .
My Inklings remian with Innovio .
Best of
How realistic is the prospect of acumapimod helping treat covid-19 in patients with copd?
GL.
very tempted to top up to my small position here today.. but such a difficult macro environment is making me hesitate.. cash is king is a lot of peoples mantra at the moment.. or gold shares even.. perhaps Mph is soon enough to be biopharma gold ? :-)
Up 5% on open
Still in 2nd gear .
A pass of 31p and straight into fifth .
Best of
Have a look at the chart as is motoring at the Nasdaq
intraday
https://uk.advfn.com/p.php?pid=staticchart&s=N%5EMREO&width=350&height=280&p=0&t=23
An announcement on partnering or using acumapimod , re covid , could change things .
Up a gear or two .
Best of
Up 14% here ahll take 2nd gear muppetito.
Back Into 2nd gear .
Best of
Now 20 % get in there.
15 % up on nasdaq.
Scooped up a load recently 10% went unoticed over here this could blow again.
Pharma Stocks in the US should see boost with Joe Biden doing well over Bernie Sanders in the Super Tuesday Elections. That may be why rising a bit on Nasdaq so far today
The american market will appreciate this news more than the uk very important milestone mreo us will see a spike this afternoon.
Boing is that an aircraft numpty?
Boing!
GL.
Great news will see how nasdaq reacts.
Thought so much....just waffle